Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 1 37Phase 1/2 22Phase NA 4Phase EARLY_PHASE1 4Phase 3 3Phase 4 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Plasma cell 1Other hematologic neoplasm 1

Conditions

Recurrence 4Multiple Myeloma 4Lymphoma 4Ovarian Neoplasms 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Solid Cancer 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1POEMS Syndrome 1Neuromyelitis Optica 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myositis 1Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1Myasthenia Gravis 1Multiple Sclerosis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 5fludarabine 4Cyclophosphamide 4pembrolizumab 2Bendamustine Hydrochloride 268Ga-pentixafor 2venetoclax 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1motexafin gadolinium 1ibrutinib 1fludarabine phosphate 1daratumumab 1brexucabtagene autoleucel 1acalabrutinib 1Vincristine 1Valproic Acid 1Transplantation 1Tablets 1Surveys and Questionnaires 1Sugars 1Stem Cell Transplantation 1Simvastatin 1Roflumilast 1Ribavirin 1Radiotherapy 1Procarbazine 1Positron-Emission Tomography 1Pemetrexed 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma × fludarabine × Clear all
NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06986434 2026-04-08

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Affiliated Hospital to Academy of Military Medical Sciences

Phase EARLY_PHASE1 Not yet recruiting
20 enrolled
LymphoidPlasma cell

Lymphoma, Recurrence, Neoplasms, Plasma Cell

NCT06756321 2025-01-03

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Affiliated Hospital of Nantong University

Phase EARLY_PHASE1 Recruiting
9 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT06532643 2024-09-19

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Shanghai First Song Biotechnology Co., LTD

Phase EARLY_PHASE1 Recruiting
9 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡